CoChat

HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study

Open access
Naranbhai, Vivek, Viard, Mathias, Dean, Michael, Groha, Stefan, Braun, David A, Labaki, Chris, Shukla, Sachet A, Yuki, Yuko, Shah, Parantu, Chin, Kevin, Wind-Rotolo, Megan, Mu, Xinmeng Jasmine, Robbins, Paul B, Gusev, Alexander, Choueiri, Toni K, Gulley, James L, Carrington, Mary · 2022 · The Lancet Oncology
Cited by 113

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

Background: Predictive biomarkers could allow more precise use of immune checkpoint inhibitors (ICI) in treating advanced cancers. Given the central role of HLA molecules in immunity, variation at the HLA loci may differentially impact response to ICI. The aim of this epidemiological study was to determine the effect of HLA-A*03 as a biomarker for predicting response to immunotherapy. Methods: We studied clinical outcomes (overall survival, progression free survival or objective response) of treatment for advanced cancer in eight cohorts, including 3,339 patients treated with various ICI agents and 10,867 treated with alternative therapies. We initially modelled the association of HLA amino acid variation, followed by detailed analysis of HLA-A*03 on clinical outcomes, with replication in additional cohorts. Findings: HLA-A*03 associated in an additive manner with reduced survival after immune checkpoint inhibition (ICI) treatment in a discovery cohort (hazard ratio, 1·54 per HLA-A*03 allele; 95% confidence interval [CI] 1·20-1·96, p<0·001), validation cohort (hazard ratio, 1·22 per HLA-A*03 allele; 95% CI 1·05-1·42, p=0·009) and clinical trial for bladder cancer (hazard ratio, 1·36 per HLA-A*03 allele; CI 1·005-1·851, p=0·05). The HLA-A*03 effect was observed across ICI agents and tumor types, but not in patients treated with alternative therapies. HLA-A*03+ patients had shorter progression-free survival in three clinical trials of nivolumab for renal cell cancer (RCC, hazard ratio, 1·31; 95% CI 1·0-1·71, p=0·04), but not in the control arm. Objective responses were observed in 0% (0/8) of HLA-A*03 homozygotes in the ICI arm. HLA-A*03 associated with shorter progression-free survival in patients receiving ICI in another randomized clinical trial for RCC (avelumab/axitinib; hazard ratio, 1·59 per HLA-A*03 allele; 95%CI 1·16-2·16, p=0·004), but not those receiving control therapy. Objective responses rate was 12·5% (1/8) among HLA-A*03 homozygotes in the ICI arm. HLA-A*03 associated with impaired outcome in meta-analysis of all 3,339 ICI treated patients at genome-wide significance (p=2·01x10−8, I2=0%, 95% CI 0%-0·76%). Interpretation: HLA-A*03 carriage should be considered in decisions regarding cancer therapy involving ICI. Funding: NIH, Merck KGaA, Darmstadt, Germany and Pfizer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(21)00582-9

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 113

Metadata

Authors
Naranbhai, V., Viard, M., Dean, M., Groha, S., Braun, D. A., Labaki, C., Shukla, S. A., Yuki, Y., Shah, P., Chin, K., Wind-Rotolo, M., Mu, X. J., Robbins, P. B., Gusev, A., Choueiri, T. K., Gulley, J. L., & Carrington, M.
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2022-01
Volume
23
Issue
1
Pages
172-184
ISSN
1470-2045 (ISSN-L)
OpenAlex
W4200548051
Cited by
113
References
11
FWCI
6.69
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study. https://app.cochat.ai/papers/10.1016/s1470-2045(21)00582-9
The paper
Naranbhai, V., Viard, M., Dean, M., Groha, S., Braun, D. A., Labaki, C., Shukla, S. A., Yuki, Y., Shah, P., Chin, K., Wind-Rotolo, M., Mu, X. J., Robbins, P. B., Gusev, A., Choueiri, T. K., Gulley, J. L., & Carrington, M. (2022). HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(21)00582-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.